Other OTC - Delayed Quote USD

Eloxx Pharmaceuticals, Inc. (ELOX)

0.8058

+0.0208

(+2.65%)

At close: April 26 at 2:34 PM EDT

Key Events

Loading Chart for ELOX

9/21 12:03 PM

DELL

Previous Close 0.7850
Open 0.7900
Bid --
Ask --
Day's Range 0.7500 - 0.8297
52 Week Range 0.4000 - 10.9000
Volume 1,985
Avg. Volume 7,580
Market Cap (intraday) 2.533M
Beta (5Y Monthly) 2.76
PE Ratio (TTM) --
EPS (TTM) -8.8800
Earnings Date Apr 29, 2024 - May 5, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 30.00

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

www.eloxxpharma.com

18

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ELOX

32.85%

S&P 500

6.92%

1-Year Return

ELOX

88.17%

S&P 500

25.26%

3-Year Return

ELOX

99.09%

S&P 500

22.00%

5-Year Return

ELOX

99.83%

S&P 500

74.29%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Eloxx Pharmaceuticals, Inc.

0.8058

+2.65%

Mkt Cap 2.533M

Industry Biotechnology

Innate Pharma S.A.

2.4600

+2.50%

Mkt Cap 198.871M

Industry Biotechnology

Can-Fite BioPharma Ltd.

1.9800

+3.13%

Mkt Cap 9.881M

Industry Biotechnology

Alterity Therapeutics Limited

0.0002

0.00%

Mkt Cap 20.5M

Industry Biotechnology

Chemomab Therapeutics Ltd.

0.6399

-2.90%

Mkt Cap 9.09M

Industry Biotechnology

Dermata Therapeutics, Inc.

0.3427

-3.74%

Mkt Cap 2.283M

Industry Biotechnology

Zura Bio Limited

0.4000

+14.32%

Mkt Cap -

Industry Biotechnology

180 Life Sciences Corp.

0.0100

+11.11%

Mkt Cap -

Industry Biotechnology

Tevogen Bio Holdings Inc.

0.0525

+4.79%

Mkt Cap -

Industry Biotechnology

Ensysce Biosciences, Inc.

0.0180

-40.00%

Mkt Cap -

Industry Biotechnology

Cadrenal Therapeutics, Inc.

0.4305

+1.63%

Mkt Cap 6.892M

Industry Biotechnology

Valuation Measures

As of 4/26/2024

Market Cap

2.53M
Enterprise Value

3.52M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

-0.19

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-73.24%
Return on Equity (ttm)

--
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-20.48M
Diluted EPS (ttm)

-8.8800

Balance Sheet and Cash Flow

Total Cash (mrq)

4.78M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-8.25M

Analyst Price Targets

30.00

30.00 Average

0.8058 Current

30.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Earnings

Consensus EPS

Fair Value

0.8058 Current

Dividend Score

0 Low

ELOX

Sector Avg.

100 High

Hiring Score

0 Low

ELOX

Sector Avg.

100 High

Insider Sentiment Score

0 Low

ELOX

Sector Avg.

100 High

CYCN Cyclerion Therapeutics, Inc.

2.9300

-6.69%

EVLO Evelo Biosciences, Inc.

0.0495

+8.32%

CWBR CohBar, Inc.

0.8801

+10.01%

AVRO AVROBIO, Inc.

1.2100

+2.11%

ATXI Avenue Therapeutics, Inc.

6.20

-29.35%

MRKR Marker Therapeutics, Inc.

4.2900

-4.24%

HOTH Hoth Therapeutics, Inc.

1.1600

0.00%

PHIO Phio Pharmaceuticals Corp.

0.6820

+1.34%

ARDS Aridis Pharmaceuticals, Inc.

0.0650

0.00%

SYBX Synlogic, Inc.

1.8700

-1.06%

KZR Kezar Life Sciences, Inc.

0.8049

+1.89%

GRTX Galera Therapeutics, Inc.

0.1861

-10.31%

VRCA Verrica Pharmaceuticals Inc.

6.87

+3.31%

NRBO NeuroBo Pharmaceuticals, Inc.

3.1400

+2.61%

XCUR Exicure, Inc.

0.5001

-1.56%

FULC Fulcrum Therapeutics, Inc.

7.14

+0.14%